scholarly journals A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors

2021 ◽  
Author(s):  
Byoung Chul Cho ◽  
Ji-Youn Han ◽  
Sang-We Kim ◽  
Ki Hyeong Lee ◽  
Eun Kyung Cho ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
Egfr T790m

EGFR tyrosine kinase inhibitors in the treatment of advanced non-small cell lung cancer

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 19117-19117
Author(s):  
D. M. Kowalski ◽  
M. Krzakowski ◽  
P. Jaskiewicz ◽  
A. Janowicz-Zebrowska ◽  
M. Glogowski
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Tyrosine Kinase Inhibitors ◽  
Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document